SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

OMXC 20 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Genmab: Click to view the issuer\'s details

Last update : 25/05/2014  >View issuer details

2020.01.06 | 15:54 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab to Present at the 38th Annual J.P. Morgan Healthcare Conference - HTML (w)

2019.12.19 | 16:19 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics - HTML (w)

2019.12.09 | 14:27 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab to Hold 2019 R&D Update and ASH Data Review Meeting - HTML (w)

2019.12.05 | 23:32 | Periodic information / Internal Control & Corporate Governance

English version HTML (w) Mail

puce Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Employees in Genmab - HTML (w)

2019.12.05 | 09:49 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen - HTML (w)

2019.11.12 | 20:02 | Permanent Information Releases / Operations

English version HTML (w) Mail

puce Capital Increase in Genmab as a Result of Employee Warrant Exercise - HTML (w)

2019.11.06 | 17:01 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce Genmab Announces Financial Results for the First Nine Months of 2019 - HTML (w)

2019.11.06 | 15:19 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Genmab Announces Data to be Presented at 2019 ASH Annual Meeting - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 149